CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2006-01-06): Assay detects interferon antibodies, drug bioactivity in hepatitis C patients

Clinical

Assay detects interferon antibodies, drug bioactivity in hepatitis C patients

Last Updated: 2006-01-06 15:10:45 -0400 (Reuters Health)

NEW YORK (Reuters Health) - German researchers have developed a new screening system to identify interferon-neutralizing antibodies in patients with hepatitis C who are not responding to interferon alpha therapy.

The assay includes a real-time RT-PCR test that identifies MxA expression in peripheral blood mononuclear cells. MxA is a GTPase induced by interferon that is a "highly specific and reliable" marker for the drug's bioactivity, Dr. Georg Kochs of the Institute for Medical Microbiology and Hygiene in Freiburg and colleagues write in the January issue of the Journal of Medical Virology.

Dr. Kochs and his team used the assay to identify interferon alpha-neutralizing antibodies in sera from 3 of 38 patients not responding to interferon, but did not find the antibodies in 24 patients with hepatitis C who responded to interferon therapy or in 21 healthy controls.

The researchers also found a correlation between presence of the antibodies and a lack of MxA induction after interferon treatment, indicating a "complete lack of IFN bioactivity."

The role of anti-interferon antibodies in interferon resistance to hepatitis C "is still a matter of debate," the researchers note. "This new and convenient bioassay constitutes a helpful tool for answering this important question."

The test, based on a reporter plasmid containing the luciferase gene controlled by the Mx1 promoter, does not require special bioassay conditions, and is both convenient and sensitive, the researchers note. They suggest that it could be used to identify patients who are not responding to interferon early in therapy and monitor them for the development of interferon-neutralizing antibodies.

"The data obtained should be used to optimize further treatment and possibly to identify alternative interferon preparations not neutralized by the patient's serum," the researchers conclude.

J Med Virol 2006;78:74-82.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.